Vaginal Estrogen or Moisturizer During Aromatase-Inhibitor Treatment?

Dryness that persists during breast-cancer treatment deserves a specific treatment discussion. Bring the names of products you tried, how often you used them and which activities still hurt.

What VEMORA compared

The open-label trial reported 23 postmenopausal breast-cancer survivors with estrogen-receptor-positive disease taking aromatase inhibitors: 11 received vaginal estrogen and 12 received Replens moisturizer for 24 weeks. Estrogen treatment used Vagifem tablets or an Estring ring; this was not a randomized ring-versus-tablet comparison.¹

Dryness and painful sex improved more with estrogen, but libido, orgasm, sexual satisfaction and partner-relationship measures did not differ significantly. Knowing their treatment could influence symptom reports. The small sample limits confidence.¹

Estradiol measurements cannot answer the recurrence question

Two participants had above-threshold estradiol at week 24; both reported preceding aromatase-inhibitor nonadherence. That observation does not establish why the measurements increased.¹

The registry lists breast-cancer recurrence over five years as an exploratory outcome. A 24-week symptom report cannot answer that question, and a blood hormone measurement is not a recurrence outcome.¹²

How guidance frames the choice

In the United States, ACOG³ recommends nonhormonal approaches first. When these have not adequately helped, its consensus allows consideration of low-dose vaginal estrogen after discussing risks and benefits. For someone taking an aromatase inhibitor, the shared decision involves the patient, gynecologist and oncologist. This guidance predates VEMORA.³

UK NICE⁴ guidance likewise calls for a breast-cancer specialist when symptoms persist despite nonhormonal treatment during adjuvant aromatase-inhibitor therapy. It states that whether vaginal estrogen affects recurrence risk remains unknown. Its discussion distinguishes estrogen-receptor-positive disease from estrogen-receptor-negative disease; the reassurance offered for the latter cannot be transferred to this trial’s population.⁴

For your appointment, separate the symptom goal from the uncertainty you want explained. “I want to sit comfortably” and “penetration hurts despite moisturizer” describe different priorities. Ask which option fits your cancer history, who will coordinate the decision and when the response will be reviewed. If symptoms are making your cancer medicine difficult to continue, say so directly; arrange a treatment review before changing it yourself.

My Body Changed. Now What? includes an “After Breast Cancer” section with a visit brief for treatments tried, symptom burden and the clinicians who should participate. Use it to prepare that conversation.